| Neoantigen-directed immune escape in lung cancer evolution R Rosenthal, EL Cadieux, R Salgado, MA Bakir, DA Moore, CT Hiley, ... Nature 567 (7749), 479-485, 2019 | 850 | 2019 |
| Fc effector function contributes to the activity of human anti-CTLA-4 antibodies FA Vargas, AJS Furness, K Litchfield, K Joshi, R Rosenthal, E Ghorani, ... Cancer cell 33 (4), 649-663. e4, 2018 | 595 | 2018 |
| Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T Cells to protect tumour cells MA Lakins, E Ghorani, H Munir, CP Martins, JD Shields Nature communications 9 (1), 948, 2018 | 538 | 2018 |
| Pan-cancer deconvolution of tumour composition using DNA methylation A Chakravarthy, A Furness, K Joshi, E Ghorani, K Ford, MJ Ward, EV King, ... Nature communications 9 (1), 3220, 2018 | 295 | 2018 |
| Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia E Ghorani, B Kaur, RA Fisher, D Short, U Joneborg, JW Carlson, A Akarca, ... The Lancet 390 (10110), 2343-2345, 2017 | 206 | 2017 |
| Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells E Menares, F Gálvez-Cancino, P Cáceres-Morgado, E Ghorani, E López, ... Nature communications 10 (1), 4401, 2019 | 205 | 2019 |
| Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma L Au, E Hatipoglu, MR de Massy, K Litchfield, G Beattie, A Rowan, ... Cancer cell 39 (11), 1497-1518. e11, 2021 | 198 | 2021 |
| Regulatory T cells restrain interleukin-2-and Blimp-1-dependent acquisition of cytotoxic function by CD4+ T cells A Śledzińska, MV de Mucha, K Bergerhoff, A Hotblack, DF Demane, ... Immunity 52 (1), 151-166. e6, 2020 | 198 | 2020 |
| Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer K Joshi, MR de Massy, M Ismail, JL Reading, I Uddin, A Woolston, ... Nature medicine 25 (10), 1549-1559, 2019 | 181 | 2019 |
| CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity I Solomon, M Amann, A Goubier, F Arce Vargas, D Zervas, C Qing, ... Nature cancer 1 (12), 1153-1166, 2020 | 151 | 2020 |
| Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma E Ghorani, R Rosenthal, N McGranahan, JL Reading, M Lynch, KS Peggs, ... Annals of oncology 29 (1), 271-279, 2018 | 138 | 2018 |
| The T cell differentiation landscape is shaped by tumour mutations in lung cancer E Ghorani, JL Reading, JY Henry, MR Massy, R Rosenthal, V Turati, ... Nature cancer 1 (5), 546-561, 2020 | 95 | 2020 |
| Intraplacental choriocarcinoma: systematic review and management guidance L Jiao, E Ghorani, NJ Sebire, MJ Seckl Gynecologic Oncology 141 (3), 624-631, 2016 | 95 | 2016 |
| Cell communication with the neural plate is required for induction of neural markers by BMP inhibition: evidence for homeogenetic induction and implications for Xenopus animal … C Linker, I De Almeida, C Papanayotou, M Stower, V Sabado, E Ghorani, ... Developmental biology 327 (2), 478-486, 2009 | 64 | 2009 |
| Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional CD4+ PD-1+ cells and inferior survival in patients with newly diagnosed multiple myeloma N Alrasheed, L Lee, E Ghorani, JY Henry, L Conde, M Chin, ... Clinical Cancer Research 26 (13), 3443-3454, 2020 | 60 | 2020 |
| When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): a national analysis on over 4,000 … K Balachandran, A Salawu, E Ghorani, B Kaur, NJ Sebire, D Short, ... Gynecologic oncology 155 (1), 8-12, 2019 | 57 | 2019 |
| Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment YNS Wong, K Joshi, P Khetrapal, M Ismail, JL Reading, MW Sunderland, ... Journal of Experimental Medicine 215 (11), 2748-2759, 2018 | 57 | 2018 |
| Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study A Braga, G Paiva, E Ghorani, F Freitas, LGC Velarde, B Kaur, N Unsworth, ... The Lancet Oncology 22 (8), 1188-1198, 2021 | 55 | 2021 |
| Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience E Ghorani, HH Wong, C Hewitt, J Calder, P Corrie, B Basu Oncology 89 (5), 281-287, 2015 | 55 | 2015 |
| Cancer cell-intrinsic mechanisms driving acquired immune tolerance E Ghorani, C Swanton, SA Quezada Immunity 56 (10), 2270-2295, 2023 | 41 | 2023 |
Sergio A. QuezadaUCL Cancer Instituteucl.ac.uk üzerinde doğrulanmış e-posta adresine sahip